Methods for Identifying Candidate Therapeutics for Multiple Sclerosis Using Single-Cell RNA Sequencing of Cerebrospinal Fluid and Transcriptomic Reversal Scoring — Provisional Patent Specification

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification for USPTO filing. Discloses computational methods for drug repurposing in multiple sclerosis (MS) using single-cell RNA sequencing of cerebrospinal fluid (CSF) from 6 MS patients and 6 IIH neurological controls, variational autoencoder-based dimensionality reduction (scVI), Leiden clustering, Wilcoxon differential expression (MS vs IIH primary, plus T cell, B cell, monocyte, and pro-MS cluster subsets), and LINCS L1000 transcriptomic reversal scoring. Application to GSE138266 across 26 independent Enrichr queries identified 236 NOVEL_ALL candidates. Top candidates: SA-440832 (priority 124,503), AMG-837 (TRPV1 antagonist, 76,398), R-547 (CDK inhibitor, 61,143), RG-7388 (MDM2 inhibitor, 60,244), SAR405838 (MDM2 inhibitor, 59,365), LXR-623 (LXR agonist, 55,577), IPI-145/duvelisib (PI3Kδ/γ inhibitor, 52,368). IPI-145 implicates dual PI3K inhibition as a novel intrathecal MS therapeutic strategy. LXR-623 addresses both neuroinflammation suppression and remyelination promotion. MDM2 inhibitors extend cross-disease p53-MDM2 axis findings to three independent tissues. Inventor: Glen Charles Ritschel, Ritschel Research, Tega Cay, SC. Micro-entity filing.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Computational Drug Discovery Methods Single-cell and spatial transcriptomics

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
21 March 2026
Language
EN